tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Mirum Pharmaceuticals price target raised to $82 from $77 at Raymond James

Raymond James raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $82 from $77 and keeps a Strong Buy rating on the shares. The company reported another “beat-and-raise” quarter with broad increases in net sales across the Livmarli and bile acid product lines, the analyst tells investors in a research note. The firm remains bullish on Mirum’s outlook.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1